Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces the launch of its upgraded VivoSight OCT scanner with a new software technology that provides additional features for dermatologists to investigate skin lesions such as non-melanoma skin cancer.

The VivoSight OCT scanner enables the dermatologist to see vertical cross-sectional images of sub-surface skin tissue to depths of 1-1.5 mm in high definition, providing the clinician with important information about the type, depth and lateral spread of the skin lesion that is not possible to determine from its surface visual appearance. Our technology allows the clinician to make more accurate, earlier diagnosis and treatment decisions than would otherwise be possible without taking a biopsy.

Now, Michelson Diagnostics has added the capability to simultaneously display horizontal ‘en-face’ images at any desired depth in the imaged region, showing a ‘field of view’ of 6 mm x 6 mm.

Potentially, the ability of VivoSight OCT to help clinicians diagnose further types of skin condition (such as pigmented lesions) could be developed. Professor Dr. med. Julia Welzel, said: “The capability of VivoSight to provide en-face section as well as vertical section OCT images is very welcome because we will have more detailed insight into anatomical features like shape of the dermoepidermal junction and three-dimensional distribution of tumour nests. The vertical sections can be compared with histology, whereas the horizontal sections provide the third dimension for dermoscopy.”

Jon Holmes, CEO of Michelson Diagnostics, added: “At Michelson Diagnostics, we strive to provide clinicians with cutting edge technology to enable accurate diagnosis of skin conditions. The additional functionality of this software places our VivoSight system at the forefront of dermatology diagnosis, reducing the need for biopsy and facilitating improved patient outcomes.”

Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam Optical Coherence Tomography (‘OCT’), that uses an advanced laser scanner to ‘see’ into tissue with unprecedented image resolution and quality of image. Multi-beam OCT has many potential clinical applications, but we are currently focusing on dermatology.

OCT system to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body. We currently generate revenues from our first commercial application of VivoSight, which is in the diagnosis of non-melanoma skin cancer (NMSC).

VivoSight has regulatory clearance in Europe, USA and Australia, for use by trained clinicians in their assessment of the patient’s medical condition. We have launched VivoSight in Germany where the VivoSight scan is reimbursed for patients with private healthcare insurance.

The Company, based in Orpington, Kent, was founded in 2006 and has 18 employees. It has sales offices in Germany and USA. It has been supported through funding from a syndicate of Venture Capital, corporate and private investors including Octopus, Catapult Ventures and Angel Investors. For more information about Michael Diagnostics, see www.michelsondiagnostics.com.

Business News:

Technology:

Miscellaneous:

Quotes

At Michelson Diagnostics, we strive to provide clinicians with cutting edge technology to enable accurate diagnosis of skin conditions. The additional functionality of this software places our VivoSight system at the forefront of dermatology diagnosis, reducing the need for biopsy and facilitating improved patient outcomes.